Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Inclusion Criteria

• •1\. Histologically or cytologically confirmed diagnosis of any cancer except leukemia
• •2\. Patients must have the presence of malignant cells in the CSF (CSF+) OR at least 2 of the 3 following features: 1) clinical signs and symptoms of LMDz 2) characteristic radiographic abnormalities , and 3) "suspicious" CSF (Chamberlain 2017)
• •3\. Patients must have an Eastern Cooperative Oncology Group performance scale of \< 3 OR Karnofsky Performance Status of \>50.
• •4\. An interval of at least 2 weeks after the end of prior radiation therapy to the brain (e.g., stereotactic radiosurgery or other-WBRT is excluded)
• •5\. An interval of at least 4 weeks following any surgical resection of brain lesions prior to treatment
• •6\. Be \> 18 years of age on the day of signing consent
• •7\. Demonstrate adequate organ function as defined in Table 2. All screening labs should be performed with 14 days of treatment initiation
• •8\. Resting baseline O2 saturation by pulse oximetry of \> 92% at rest
• •9\. Patients must have recovered from the toxic effects of prior therapies (\< Grade 1)
• •10\. Provision of signed and dated informed consent form
• +28 more criteria